Intra-Cellular Therapies, Inc.

CAPLYTA net product sales were $175.2 million in Q3 2024, up 39% versus Q3 2023. Total prescriptions grew 38% year over year and sales increased 9% sequentially versus Q2 2024. Gross-to-net was in the mid-30s in the quarter and is expected to remain in the mid-30s in Q4. SG&A was $132.1 million versus $105.2 million a year ago, and R&D was $66.8 million versus $41.6 million a year ago. Cash and investments totaled $1 billion at September 30, 2024, versus $499.7 million at December 31, 2023. For 2024, the company raised CAPLYTA net product sales guidance to $665 million-$685 million, narrowed SG&A guidance to $490 million-$510 million, and narrowed R&D guidance to $220 million-$230 million.

Sharon Mates said CAPLYTA’s growth reflects a compelling profile and strong execution, and framed the quarter as part of a broader expansion across mood disorders. She highlighted the MDD Phase III data as “truly exceptional,” emphasized favorable safety/tolerability and convenient once-daily dosing, and said the company believes CAPLYTA can become a leading treatment across bipolar depression, MDD, and schizophrenia. Her tone was confident and expansive, with repeated emphasis on patient need, market opportunity, and long-term growth.

Sanjeev Narula emphasized another strong quarter for CAPLYTA, citing $175.2 million in sales, 39% year-over-year growth, and 9% sequential growth driven by prescription demand. He noted gross-to-net was in the mid-30s and said Q4 should remain similar. He also detailed the expense base: SG&A of $132.1 million and R&D of $66.8 million, with higher spending tied to the primary care sales force expansion and multiple clinical programs. He closed by pointing to a strong balance sheet with $1 billion in cash and investments and said the company is well positioned to keep investing in CAPLYTA and the pipeline.

Analysts focused on the rationale and mix behind the new $5 billion long-term CAPLYTA target, and management said the forecast is mainly driven by bipolar depression and MDD, with schizophrenia contributing to a lesser extent. They also asked about launch pacing in MDD, and Mark Neumann said the company expects rapid uptake based on 501/502, quantitative market research, and analogs like Vraylar, while also saying the new primary care sales force should have more impact in 2025 than Q4. On pipeline topics, management said the GAD program for ITI-1284 is being run as an adjunctive study now and will shortly expand to monotherapy, and that 1284’s GAD path is the clearest regulatory route if studies are positive.